Foghorn Therapeutics (FHTX) Cash from Investing Activities (2020 - 2025)
Foghorn Therapeutics has reported Cash from Investing Activities over the past 6 years, most recently at $13.2 million for Q4 2025.
- Quarterly results put Cash from Investing Activities at $13.2 million for Q4 2025, down 40.64% from a year ago — trailing twelve months through Dec 2025 was $112.0 million (up 474.67% YoY), and the annual figure for FY2025 was $112.0 million, up 474.67%.
- Cash from Investing Activities for Q4 2025 was $13.2 million at Foghorn Therapeutics, down from $35.6 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for FHTX hit a ceiling of $77.1 million in Q2 2021 and a floor of -$159.4 million in Q1 2022.
- Median Cash from Investing Activities over the past 5 years was $24.7 million (2024), compared with a mean of $921850.0.
- Biggest five-year swings in Cash from Investing Activities: skyrocketed 3529.23% in 2021 and later plummeted 4788.35% in 2022.
- Foghorn Therapeutics' Cash from Investing Activities stood at $9.7 million in 2021, then plummeted by 167.27% to -$6.5 million in 2022, then surged by 674.54% to $37.4 million in 2023, then crashed by 40.37% to $22.3 million in 2024, then plummeted by 40.64% to $13.2 million in 2025.
- The last three reported values for Cash from Investing Activities were $13.2 million (Q4 2025), $35.6 million (Q3 2025), and $33.8 million (Q2 2025) per Business Quant data.